Starting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
|
|
- Leslie Holt
- 8 years ago
- Views:
Transcription
1 Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier Speakers Bureau Abbott, AstraZeneca, Eli Lilly, GSK, Merck, Pfizer, Sanofi- Aventis, Servier Clinical Research Abbott, Amgen, AstraZeneca, Eli Lilly, GSK, Merck, Novartis, Janssen-Ortho, Pfizer, Roche, Sanofi-Aventis, Schering Ownership none Starting Insulin Oral Hypoglycemic Agent (OHA) failure objections to insulin patient physician moving on to basal analogue how why moving on to mixed analogues OD/BID/TID 1
2 Clinical Pearls setting practice targets consistent with the recommended CDA targets understanding the benefits of tight glycemic control gaining insight into the common features of Psychological Insulin Resistance Recognizing physician barriers to reaching targets with insulin Gaining comfort with Basal insulin prescribing the 1 st step Recognizing the opportunities to use a mixed analogue insulin Hans K. 56-year-old male Diabetes since 1994 DEC well-educated, active, very diet-conscious weight 87 kg, BMI 28.4, waist 98 cm metformin 1gm 2, Actos 45mg 1, Diamicron MR 120mg 1 Breakfast Lunch Dinner Bedtime A1c 8.2 Recommended Targets for Glycemic Control Target A1C (%) Fasting/ac-meal (mmol/l) 2-hr pc-meal (mmol/l) Target most patients Normal Range for patients in whom it can be achieved safely CDA 2003 CPG, Can J Diabetes 27(Suppl 2):S
3 Lessons from UKPDS: Lower A1c = Fewer Complications Every 1% reduction in HbA 1c Risk reduction* Deaths from diabetes 21% 1% Myocardial infarctions Microvascular complications 14% 37% Peripheral vascular disorders 43% Stratton IM et al. UKPDS 35. BMJ. 2000;321: Psychological Insulin Resistance 1. Perceived loss of control over one s life 2. Lack of self-efficacy / confidence 3. Sense of personal failure 4. Implications to Disease Severity 5. Perceived lack of benefit adapted from Polonsky WH, Jackson RA. Clinical Diabetes 2004;22: Perceived Loss of Control over One s Life Once I start insulin, I ll never be able to stop. Provide a sense of control regarding insulin Present it as a temporary experiment: Try it for a month and see how you feel. Start with a therapy that minimizes lifestyle restrictions Polonsky WH, Jackson RA. Clinical Diabetes 2004;22:
4 2. Lack of Self-Efficacy/Confidence Taking insulin is too complicated. Show patients how simple insulin is to use Build patient confidence Recognize patient abilities Empower patient Keep it simple Demonstrate: have patient inject in office Polonsky WH, Jackson RA. Clinical Diabetes 2004;22: Novolin Pen4 (Novo Nordisk) HumaPen Luxura (Eli Lilly) 4
5 Supplies 3. Sense of Personal Failure I did this to myself. I should have kept going to the gym. Stress that the need for insulin is a function of the underlying disease, not an indication of failure at proper diabetes self-care Polonsky WH, Jackson RA. Clinical Diabetes 2004;22: UKPDS Progression of β-cell Loss β-cell function (%) Diagnosis Years from diagnosis Lebovitz H. Diabetes Rev 1999;7: Holman RR. Diabetes Res Clin Pract 1998;40(suppl):S21-S25. 5
6 Progression of Hyperglycemia (A1c) 9 UKPDS 8.0 ADOPT A1C (%) 8 7 % years Glyburide Chlorpropamide Metformin years Glyburide Rosiglitazone Metformin 4. Implications to Disease Severity My uncle went on insulin right before he lost his leg. Frame the insulin message properly Emphasize that Type 2 diabetes is a progressive disease and that requiring insulin is a natural part of this progression Polonsky WH, Jackson RA. Clinical Diabetes 2004;22: Perceived Lack of Benefit Insulin won t help me. Pass along the good news Review positive benefits Explain that insulin is the best way to ensure continued good health and diabetes control Polonsky WH, Jackson RA. Clinical Diabetes 2004;22:
7 Physician Barriers to Initiating Insulin relying on lifestyle - giving diet/weight loss a last chance concerns over hypoglycemia potential for weight gain lack of resources to initiate insulin and educate patient unwilling to convince reluctant patient Potential impact on patient s employment 1. Wallace, TM., Q.J. Med. 2000; 93(6): Polonsky, WH., Clinical Diabetes, 2004; 22(3): Home, PD., Pract. Diab. Int., 2003; 20(2): Type 2 Diabetes Insulin Options Basal NPH OD (or BID) Glargine OD (or BID) Detemir OD (or BID) Premixed (BID or TID) Novolin or Humulin 30/70 NovoMix30 Humalog Mix 25 Others Multiple daily injections (meal-time + basal) Initiating Insulin Consider adding bedtime intermediate-acting insulin, longacting insulin, or extended long-acting insulin analogue to daytime oral antihyperglycemic agents. Better glycemic control achieved with less insulin Less weight gain, especially when metformin continued, compared to insulin alone Decreased risk of hypoglycemia Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2003;27(Suppl 2):S
8 Normal Pancreatic Function Basal: Beta cells secrete small amounts of insulin throughout the day. Bolus: At mealtime, insulin is rapidly released in response to food. Bolus Insulin Basal Insulin Meal Meal Meal Time-Action profiles of bolus & basal insulins Plasma Insulin levels mu/l aspart/lispro 3-5 hours regular 5-8 hours NPH ~14 hours Diagrammatic representation Action curves are approximations taken from different data sources. Actual patient response will vary detemir/glargine ~24 hours Hours Achieving Target Levels with Insulin A1C target 7% (or 6%): Fix the Fasting glucose First (FFF) Start with one initial injection (basal) As beta cells fail over time, basal insulin plus oral agent may no longer keep glucose levels optimal Mealtime insulin may be added later - started at all meals, or possibly just at larger meals such as dinner 8
9 Example of an Insulin Initiation Dosage Schedule Once-daily dose of basal insulin Choices: NPH Detemir Glargine Recommended starting dose 10 IU/day Increase insulin dose by 1 IU/day until FPG target is achieved Gerstein HC. INSIGHT Study. Diabet Med 2006;23: Self-Titration of Insulin Insulin Dosage Instructions Your target fasting blood sugar level is 6 mmol/l You will inject 10 units of insulin each evening You will continue to increase by 1 unit every day until your blood sugar level is 6.5 mmol/l before breakfast Do not increase your insulin when your fasting blood sugar is 4.5 mmol/l NB - INSIGHT and TREAT to TARGET studies used an FPG target of <5.5 Alternate Algorithm Treat to Target Trial Start dose 10 units - forced weekly insulin titration schedule to target FBG 5.6 mmol/l Mean of Self-Monitored FPG values from preceding 2 days Increase of Insulin Dosage Units/Day 10 mmol/l mmol/l mmol/l mmol/l Exceptions: No increase in dosage if FPG 4 mmol/l at any time in the preceding week Decreases of 2-4 units/day/adjustment if severe hypoglycemia requiring assistance or FPG 3.1 mmol/l documented in the preceding week Adapted from Riddle MC, et al. Diabetes Care 2003;26(11):
10 Oral Hypoglycemic Agent Instructions Metformin continue at 500mg BID 1000mg BID ~30% dose-sparing effect consider renal function for dosing Sulfonylureas (glyburide, gliclazide, glimepiride) also ~30% dose-sparing increased risk of hypoglycemia TZD s (rosiglitazone, pioglitazone) discontinue ~30 40% dose-sparing not an indicated usage in Canada increased risk of CHF Insulin titration - scenario 1 Breakfast Lunch Supper Before After Before After Before After Bedtime Dose Sunday Monday Tuesday Wednesday Thursday 8.8 OHAs Metformin 1000 mg BID Glyburide 10 mg BID 10
11 Insulin titration - scenario 2 Breakfast Lunch Supper Before After Before After Before After Bedtime Dose Sunday Monday Tuesday Wednesday Thursday 7.1 OHAs Metformin 1000 mg BID Glyburide 10 mg BID Insulin Schedule Review 3 Breakfast Lunch Supper Before After Before After Before After Bedtime Dose Sunday Monday Tuesday Wednesday Thursday OHAs Metformin 1000 mg BID Morning vs Bedtime Insulin - glargine Baseline A1c: 9.1±1.0 0 Morning Glargine Bedtime Glargine Bedtime NPH A1C Change From Baseline (%) P=0.008 P<0.001 Adapted from Fritsche A et al, and the 4001 Study Group. Ann Intern Med. 2003:138:952 11
12 Morning vs Bedtime Insulin - detemir Baseline A1c: 9.1±1.0 0 Morning Detemir Bedtime Detemir Bedtime NPH A1C Change From Baseline (%) Philis-Tsimikas et al. Clinical Therapeutics. 28:10, 2006, Which Basal analogue? Variability and profile - NPH 12
13 Variability and profile - NPH & glargine Variability and profile NPH, glargine & detemir Response Variability CV (%) (Glucose infusion rate AUC0 24) 80% 70% 60% 50% 40% 30% 20% 10% 0% 68% NPH insulin p < % p < Insulin glargine 27% Insulin detemir NPH insulin Insulin glargine Insulin detemir Heise T et al. Diabetes 2004;53:
14 Nocturnal hypoglycaemia Events per subject per month Insulin detemir NPH insulin Overall p = Months I. De Leeuw et al. Diabetes Obes Metab 2005;7:73-82 Nocturnal Hypoglycemia analogue basal comparison Nocturnal Hypoglycemia Risk reduction = 32% detemir glargine p< Pieber T et al. Diabetologia 2005;48(Suppl. 1):A92 Weight gain in type 2 diabetes: UKPDS data 10.0 Conventional group Intensive group Change in weight (kg) Years from randomisation UKPDS Group (33). Lancet 1998;352:
15 Weight change in Insulin therapy studies - treat-to-target Basal comparisons Weight (kg) Insulin detemir NPH insulin Weeks K. Hermansen et al. Diabetologia 2004;47(Suppl. 1):A273 Weight change *p < 0.05, insulin detemir vs NPH insulin Insulin detemir NPH insulin Weight change (kg) * * * * * * * * * * * Standl 2004 Vague 2003 De Leeuw 2005 Pieber 2005 Pieber 2005 # Home 2004 ## Home 2004 Russell- Jones 2004 Hermansen 2004 Studies in type 2 diabetes Rašlová 2004 Haak 2005 * ### Hermansen 2006 Basal Analogue benefits Less likely to go low, especially at night Reduced fear of going low, both for patients and their families Less need for snacking less weight gain 15
16 Switching existing NPH patients NPH OD Insulin Detemir or Insulin Glargine: Switch unit for unit and give once daily NPH BID Insulin Detemir or Insulin Glargine: use~80% of total NPH dose, given once or twice daily Levemir (insulin detemir [rdna origin] injection) prescribing information. Novo Nordisk, Inc Lantus (insulin glargine) [rdna origin] injection) prescribing information. Sanofi-aventis, Hans K. 53-year-old male Diabetes since 1994 well-educated, active weight 87 kg, BMI 28.4, waist 98 cm metformin 1gm 2, Actos 45mg 1, Diamicron MR 120mg 1 Pre-meal and 2 hr post-meal glucose (mmol/l) Breakfast Lunch Dinner Bedtime A1c 9.8, 10.2 BID NPH and Regular Insulin Therapy - Compared to Normal Physiology Basal needs: NPH Bolus needs: Regular Meal Meal Meal Mayfield, JA. et al., Amer. Fam. Phys.; Aug. 2004, 70(3):
17 Multiple Daily Injections (MDI) Strive to Mimic Normal Physiology MDI insulin therapy addresses: Basal needs: Glargine, Detemir Bolus needs: Lispro, Aspart Meal Meal Meal Mayfield, JA. et al., Amer. Fam. Phys.; Aug. 2004, 70(3): Multiple Daily Injections (MDI) Strive to Mimic Normal Physiology but 4 injections MDI insulin daily therapy addresses: Basal needs: Glargine, Detemir Bolus needs: Lispro, Aspart Meal Meal Meal Mayfield, JA. et al., Amer. Fam. Phys.; Aug. 2004, 70(3): A Simpler Approach: Pre-Mixed Analogues Breakfast Lunch Dinner Normal insulin secretion Biphasic insulin aspart Insulin action 4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00 Time Nathan DM. N Engl J Med 2002;347:
18 Type 2 Diabetes Insulin Options Basal NPH QHS or BID Glargine QHS or at any time of the day Detemir QHS or BID Premixed Premixed BID or TID Others Multiple daily injections (meal-time + basal) Type 2 Diabetes Insulin Options Premixed Premixed BID or TID 30/70 insulin (novolin or humulin) Biphasic Insulin Aspart 30 (BIAsp 30; NovoMix 30 ) insulin lispro protamine (Humalog Mix25 ) BIAsp 30 (NovoMix30 ) Glucose Levels in Type 2 Diabetes * Serum glucose (mg/dl) * Aspart Mix 30/70 30/70 Premix * 0 6:00 PM 10:00 PM 8:00 AM 1:00 PM 6:00 PM Dinner Breakfast Lunch *Glucose excursions 0-4 h, P<0.05. McSorley. Clin Ther. 2002;24(4):
19 Humalog Mix25 vs 30/70: 2-hr Post-meal BG lower at Breakfast & Dinner Mean ± SEM BG (mmol/l) * Fasting Breakfast 2h pp Pre- Lunch Mean A1C 8.1 vs. 7.8, p=ns N=89 type 2 DM pts. Lunch 2h pp Pre- Dinner * Dinner 2h pp Lispro Mix25 Human Insulin Mixture 30/70 *p<0.05 Bedtime 3 AM Data derived from Roach P et al. Diabetes Care 1999;22(8): Humalog Mix25 vs 30/70: Hypoglycemia Episodes per Patient Lispro Mix25 p= Human Insulin Mixture 30/70 Roach P, et al. Clinical Therapeutics, 1999; 3: Starting or Switching BID premixed insulin Dose if using insulin - total daily dose (TDD) if new - Calculate 0.5 units/kg Frequency ½ ac-breakfast & ½ ac-supper or 2/3 of total ac-breakfast & 1/3 ac-supper. D/C secretagogues 1. Hirsch IB, et al. Clinical Diabetes 2005; 23(2): Can J Diabetes 2003;27(suppl 2):S135 19
20 Hans K. 53-year-old male Diabetes since 1994 well-educated, active weight 87 kg, BMI 28.4, waist 98 cm metformin 1gm 2, NovoMix30 30 U qam; 15 U qpm Pre-meal and 2 hr post-meal glucose (mmol/l) Breakfast Lunch Dinner Bedtime NovoMix Study design Phase subjects QD Pre-dinner x 16 wks Start with 12 U at dinner A1c 6.5% End of study If A1c > 6.5%, go to BID, d/c secretagogues Phase 2 68 subjects BID Pre-breakfast & dinner x 16 wks Add 3 U at breakfast if FPG 6.1 Add 6 U at breakfast if FPG > 6.1 A1c 6.5% End of study Phase 3 25 subjects TID TID x 16 wks Add 3 U at lunch If A1c > 6.5%, go to TID End of study Titrate according to schedule every 3 days Garber AJ, et al. Diabetes Obes Metab 2006;8:58 NovoMix Study Titration Algorithm Blood glucose (mmol/l) < >10 Dose change (U) -3 No change
21 NovoMix Study Conclusions 1. can be initiated OD and intensified to BID or TID 2. with OD dosing, 41% of patients achieved A1c < 7.0% 3. with progression to BID dosing, 70% of patients achieved A1c < 7.0% 4. with progression to TID dosing, 77% of patients achieved A1c < 7.0% 5. no significant relationship between number of injections & frequency of hypoglycemia Garber AJ, et al. Diabetes Obes Metab 2006;8:58 Starting Insulin OHA failure objections to insulin patient physician moving on to basal analogue how why moving on to mixed analogues OD/BID/TID Clinical Pearls setting practice targets consistent with CDA targets anticipating and being prepared for the common features of Psychological Insulin Resistance Recognizing our own physician barriers to insulin therapy Gaining comfort with Basal insulin prescribing as a 1 st step Recognizing the opportunities to use a mixed analogue insulin OD, BID, TID for ease of use 21
22 Resource Slides Hypoglycemia Hypoglycemia Causes: Increased physical activity Not eating on time Eating less than normal Taking too much medication/insulin The effects of drinking alcohol 22
23 Hypoglycemia Treatment Check your blood glucose right away. If you do not have your meter with you, but are experiencing symptoms, you are always safer to treat! If your blood sugar is < 4 mmol/l eat or drink 15 g of a fast acting carbohydrate such as: 3 glucose tablets, 1/2 cup of juice (half a juice box), 3 packets of sugar dissolved in water, 6 Life Savers (chew them) Wait 15 minutes, then check your blood sugar again. If your blood sugar is still < 4mmol/L, treat again. If your next meal is more than one hour a way eat a snack (15g of carbohydrates and a protein source ex: 1 oz of cheese and 7 soda crackers). 1. Pick Your Site The ideal sites for injection provide the best absorption while avoiding overuse of the same patch of skin from the lower rib edge to the upper front hip crest; and from the seam in the shirt on each side Move over by 1 cm in a straight line for each injection; shots can be given in one straight line Then move 1 cm lower and start the next line of shots across your abdomen It may be months before having to re-use the same skin site 2. Prime Your Pen Safety test Should be done before each injection and after changing cartridges Set for 2 4 units, hold pen or needle pointing upward and press dosage button until it is engaged Drops of insulin should appear from the top of the needle 23
24 3. Inject Pinch an inch of skin between thumb and forefinger of one hand Inject at a 90 o angle into the loose tissue under the skin at your chosen site Push plunger down completely Leave needle in to a count of 10 to ensure proper absorption Pull out needle Dispense in sharps container Insulin Storage Refrigerate unused insulin until use Insulin should only be used at room temperature Insulin can be kept for up to 28 days in the pen at room temperature (up to 42 days for insulin detemir) Keep insulin away from direct sunlight and high temperatures (i.e. don t leave in a car in the summer) 24
Presented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationInsulin pen start checklist
Insulin pen start checklist Topic Instruction Date & Initials 1. Cognitive Assessment 2. Insulin Delivery loading appropriate mixing priming shot dialing up dose delivery of insulin 3. Insulin type/action
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationGuidelines for Education and Training
Aim These protocols aim to provide the necessary guidance to enable insulin to be initiated safely and effectively Objectives 1. To provide the suggested procedure for the initiation of insulin for people
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationInsulin and Diabetes
Insulin What is Insulin? Insulin is a hormone produced by special cells in the pancreas These cells that are produced are called beta cells Insulin allows the glucose from food we eat to enter the cells
More informationOnset Peak Duration Comments
Rapid- Acting 5-15 minutes 0.5-3 hours 3-5 hours Meal should be available before administering, ideally taking within 10 minutes of eating). Good in refrigerator (36-46 F) until expiration date. Protect
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationChapter 8 Insulin: Types and Activit y
Chapter 8 Insulin: Types and Activit y H. Peter Chase, MD Satish Garg, MD INSULIN Before insulin was discovered in 1921, there was little help for people who had type 1 diabetes. Since then, millions of
More informationInsulin. Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs
Insulin Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs Insulins Rapid-acting Inhaled Short-acting Basal/ Intermediate Basal Pre-mixed
More informationUW MEDICINE PATIENT EDUCATION. Using Insulin. Basic facts about insulin and self-injection. What is insulin? How does diabetes affect the body?
UW MEDICINE PATIENT EDUCATION Using Insulin Basic facts about insulin and self-injection This handout explains what insulin is, the different types of insulin, how to store it, how to give an injection
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationInjectable Insulin During Pregnancy
Injectable Insulin During Pregnancy What is insulin? Insulin is a hormone made by the pancreas. The pancreas is a small organ that lies behind and below the stomach. Insulin allows the food you eat to
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationEveryday Practice: Diabetes Mellitus
THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationTYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.
TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationGuideline for Insulin Therapeutic Review in patients with Type 2 Diabetes
Diabetes Sans Frontières Guideline for Insulin Therapeutic Review in patients with Type 2 Diabetes 1. Introduction This guideline has been developed in order to support practices to undertake insulin therapeutic
More informationInsulin Pens. Basic facts. What is insulin? What are the different types of insulin?
UW MEDICINE PATIENT EDUCATION Insulin Pens Basic facts This handout explains what insulin is, the different types of insulin, how to store it, how to give an injection with an insulin pen, and other important
More informationDIABETES - INSULIN INITIATION - BACKGROUND INFORMATION (1)
DIABETES - INSULIN INITIATION - BACKGROUND INFORMATION (1) KEY PRINCIPLES Many patients with Type 2 diabetes will require insulin therapy. In the UKPDS over 50% of patients by 6 years required additional
More informationApproximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
More informationMany patients with type 2 diabetes will ultimately need
SUPPLEMENT TO JAPI april 2011 VOL. 59 17 Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationAgainst All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making
SESSION 3 10:30am 12pm Against All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making SPEAKERS Frank Lavernia, MD George Dailey III, MD Carol Wysham, MD Presenter Disclosure
More informationHow To Initiate Insulin
Initiation and Titration of Insulin Analogs in the Patient with Type 2 Diabetes Supported by an educational grant from Novo Nordisk Inc. This program is supported by an educational grant from Novo Nordisk
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationSession 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,
More informationIntroduction to Insulin. Your guide to taking insulin
Introduction to Insulin Your guide to taking insulin Introduction Insulin helps control the level of blood glucose in the body. Everyone with type 1 diabetes must take insulin, and many people with type
More informationSession 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationInsulin T Y P E 1 T Y P E 2
T Y P E 1 T Y P E 2 INSULIN There are many different insulins for many different situations and lifestyles. This section should help you and your doctor decide which insulin or insulins are best for you.
More informationEducational Objectives. Type 2 Diabetes: a progressive condition. Insulin Delivery Devices. Insulin we may wait too long
Educational Objectives Insulin Delivery Devices James Bennett RPh, FACA, CDE Director of Clinical Services at James Bennett Apothecary Corinth Mississippi After viewing this program, participants should
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationINSULIN INITIATION IN TYPE 2 DIABETES IN PRIMARY CARE
INSULIN INITIATION IN TYPE 2 DIABETES IN PRIMARY CARE We welcome feedback on this policy and the way it operates. We are interested to know of any possible or actual adverse impact that this policy/procedure
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More information10 to 30 minutes ½ to 3 hours 3 to 5 hours. 30 60 minutes 1 to 5 hours 8 hours. 1 to 4 hours
Insulin Action There are several types of insulin. They are classified by how long they act: very fast, fast, slow and very slow acting. Each type of insulin has a certain time period in which it works.
More informationFunc%onal insulin therapy: rela%onship to carbohydrate intake
Func%onal insulin therapy: rela%onship to carbohydrate intake Prof. Andrej Janež MD, PhD University Medical Centre Ljubljana, Slovenia Conflict of interests Merck Sharp&Dohme, Novo Nordisk, NovarEs, Boehringer
More information2010 Partners & Peers for Diabetes Care, Inc. www.partnersandpeers.org
Without a working knowledge of the way insulin works in your body it is very difficult to effectively manage diabetes... Kind of like driving a car without knowing how to use the gas pedal and brakes...
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationA 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial)
CLINICAL RESEARCH STUDY A 1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial) David S. Oyer, MD, a Mark D. Shepherd, MD, b Franklin C. Coulter, MD, c Anuj
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationFundamentals of Diabetes Care Module 5, Lesson 1
Module 5, Lesson 1 Fundamentals of Diabetes Care Module 5: Taking Medications Healthy Eating Being Active Monitoring Taking Medication Problem Solving Healthy Coping Reducing Risks Foundations For Control
More informationStarting or Changing Insulin Therapy For the Generalist Physician
Starting or Changing Insulin Therapy For the Generalist Physician SGIM National Meeting 2008 DC Dugdale, MD, FACP Division of GIM, University of Washington Dawn E. DeWitt MD, FACP, FRACP University of
More informationHow to Switch Between Insulin Products
Detail-Document #251005 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2009 ~ Volume 25 ~ Number 251005 How to Switch Between Insulin
More informationTHE INS AND OUTS OF INSULIN. Mary Beth Wald, RN,BSN,CDE
THE INS AND OUTS OF INSULIN Mary Beth Wald, RN,BSN,CDE WHAT HAPPENS IN MY BODY? When we eat, the food gets changed into glucose, a type of sugar. Glucose travels in the blood to all the cells in your body
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationINSULIN FOR GESTATIONAL and PREGESTATIONAL DIABETES
INSULIN FOR GESTATIONAL and PREGESTATIONAL DIABETES There have been several changes in the management of diabetes during pregnancy, including the use of insulin analogs. The Sweet Success Guidelines, revised
More informationEducational program for people with diabetes Insulin Special situations
Educational program for people with diabetes 3 Insulin Special situations Inv.: 1-6-14730 (Hôtel-Dieu, Hôpital Fleurimont) Version revised by members of the Centre de jour du diabète de l Estrie team :
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationResident s Guide to Inpatient Diabetes
Resident s Guide to Inpatient Diabetes 1. All patients with diabetes of ANY TYPE, regardless of reason for admission, must have a Hemoglobin A1C documented in the medical record within 24 hours of admission
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationUsing human insulin in line with the NICE guideline on type 2 diabetes:
Using human insulin in line with the NICE guideline on type 2 diabetes: Inside: Insulin initiation in type 2 diabetes: What should we be doing? Matthew Oldfield Human insulin in clinical practice: A series
More information